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Abstract
Opiates produce significant and persistent changes in synaptic transmission; knowledge of the proteins involved in these
changes may help to understand the molecular mechanisms underlying opiate dependence. Using an integrated
quantitative proteomics and systems biology approach, we explored changes in the presynaptic protein profile following a
paradigm of chronic morphine administration that leads to the development of dependence. For this, we isolated
presynaptic fractions from the striata of rats treated with saline or escalating doses of morphine, and analyzed the proteins
in these fractions using differential isotopic labeling. We identified 30 proteins that were significantly altered by morphine
and integrated them into a protein-protein interaction (PPI) network representing potential morphine-regulated protein
complexes. Graph theory-based analysis of this network revealed clusters of densely connected and functionally related
morphine-regulated clusters of proteins. One of the clusters contained molecular chaperones thought to be involved in
regulation of neurotransmission. Within this cluster, cysteine-string protein (CSP) and the heat shock protein Hsc70 were
downregulated by morphine. Interestingly, Hsp90, a heat shock protein that normally interacts with CSP and Hsc70, was
upregulated by morphine. Moreover, treatment with the selective Hsp90 inhibitor, geldanamycin, decreased the somatic
signs of naloxone-precipitated morphine withdrawal, suggesting that Hsp90 upregulation at the presynapse plays a role in
the expression of morphine dependence. Thus, integration of proteomics, network analysis, and behavioral studies has
provided a greater understanding of morphine-induced alterations in synaptic composition, and identified a potential novel
therapeutic target for opiate dependence.
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Introduction
Repeated exposure to opiates, such as morphine, produces
significant and persistent changes in synaptic transmission and
plasticity that may contribute to altered behaviors associated with
addiction, dependence and withdrawal. While the molecular and
cellular mechanisms underlying these long-lasting changes are not
fully understood, substantial evidence shows that opiates play a
critical role in the modulation of neurotransmitter release,
particularly in the mesolimbic dopaminergic system. Chronic
morphine exposure increases dopamine signaling in structures of
this system [1–6], including the ventral striatum, involved in
reward [7]; and the dorsal striatum, involved in craving and
relapse [8]. Since reward, craving and relapse contribute to the
development and maintenance of opiate addiction, it is likely that
presynaptic proteins involved in the regulation of neurotransmitter
release in the striatum participate in the synaptic adaptations
mediating opiate addiction, dependence and withdrawal.
Given the importance of presynaptic neurotransmitter release in
drug addiction, we undertook a quantitative subcellular proteomic
analysis to investigate the effects of morphine on striatal presynaptic
protein levels. Proteomics servesas a powerful tool to reveal changes
in protein abundance in response to drug administration [9]. While
many studies have described proteome changes in different brain
regions [10–16] and cell culture preparations [17–18] following
chronic morphine administration, few have examined morphine-
induced changes in the synaptic subproteome and none have used
network analysis methods to predict novel protein complexes and
signaling pathways altered by morphine.
Here we used an integrated proteomics, graph theory-inspired
network analysis, and behavioral approach to elucidate the
presynaptic molecular events induced by repeated morphine
administration. This has enabled a greater understanding of
morphine-induced alterations in synaptic composition, and has
allowed the identification of potential therapeutic targets for opiate
dependence and addiction.
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Protein identification and quantification
To identify and quantify proteins regulated by morphine,
presynaptic (PRE) proteins from saline- and morphine-treated
rats were subjected to differential isotopic labeling and LC-MS/
MS analysis. Five experiments were performed, using forward
(saline=light, morphine=heavy) and reverse (saline=heavy,
morphine=light) labeling (Table S1). A representative spectrum
showing a decrease in NSF, a candidate protein, upon forward
and reverse labeling is shown in Fig. 1A. Analysis of the MS/MS
spectra led to the identification of 175 proteins (Table S2), 143 of
which were quantified by determining the peak intensity of the
labeled peptides (Fig. 1B). Only 30 of these proteins were
robustly and consistently altered by morphine treatment; the
majority of which were downregulated (Table 1). We confirmed
the results from quantitative proteomic studies using Western
blotting by verifying the decrease in some of these proteins from
a separate set of saline- and morphine-treated animals (Fig. 2).
The 30 proteins, included in a list designated as the ‘‘seed list’’,
belong to the following groups: vesicle trafficking (NSF, syntaxin
binding protein 1); signaling (b1, b2, b3,a n daolf subunits of
heterotrimeric G proteins), cytoskeleton-associated (septin 7,
tubulin beta chain 7), chaperone (heat shock cognate 71 kDa or
Hsc70), and cell adhesion (contactin 1, NCAM1). Several of
these proteins have established roles in synaptic plasticity, while
others have been reported to be altered in different paradigms of
morphine treatment [10,19,20].
Network Analysis: Integration of Proteomics Data into a
PPI Network
To enrich the list and identify a network of proteins
downregulated by morphine, we used the Genes2Networks
[21] analysis (see Methods). Pairs of proteins from the seed list
were connected via shared intermediates from a background
dataset that was generated by combining databases of mamma-
lian protein-protein interactions. This analysis resulted in a
network containing 263 interactions among 28 proteins from the
seed list, using 98 intermediates from the background dataset
(Fig. 3). The clustering coefficient of this network is significantly
higher (0.14) than the average clustering coefficient (0.086)
computed from 100 shuffled networks created from the original
topology (p,0.01). Using a binomial proportions test [21,22], we
found 38 intermediates from the background dataset to
significantly (score.2) interact with proteins from the seed list.
Of these, 21 proteins were considered highly significant
(score.3).
Since functionally related nodes are likely to interact with each
other while being more separate from the rest of the network [23],
we sought to identify clusters within our network, consisting of
areas in the network where nodes are more densely connected to
each other. This allowed us to generate predictions of other
proteins likely to be modulated by morphine. We identified 3
clusters with k=4 and 10 clusters with k=3 (Figure S1). These
clusters are likely to consist of protein complexes or signaling
pathways with specific presynaptic functions.
Figure 1. Representative spectra of NSF following differential isotopic labeling and LC-MS/MS. Protein extracts from striatal PRE
fractions of saline- and morphine-treated rats were labeled either with succinic anhydride (light) or deuterated succinic anhydride (heavy) and
analyzed by LC-MS/MS. (A) Combined MS scans showing the relative abundance of the peak pair with mass/charge (m/z) ratios 495.3 and 499.3
(indicated by the arrows). The morphine/saline ratio with forward labeling (saline=light, morphine=heavy; indicated in black) was ,0.55. This ratio
was reversed (morphine/saline ratio ,1.6) with reverse labeling (saline=heavy (H); morphine=light (L); indicated in red). (B) Overlaid tandem MS of
precursor ions m/z 495.3 (black) and m/z 499.3 (red) corresponding to the tryptic peptide L*FGLLK* with labels present on N-terminal amine and C-
terminal lysine (indicated by the *). Mascot database search showed that the tryptic peptide was derived from N-ethylmaleimide sensitive factor
(NSF).
doi:10.1371/journal.pone.0025535.g001
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Some of the predictions generated by the cluster analysis were
verified using Western blot analysis (Fig. 4). For this, we focused on
two main clusters (outlined in Fig. 3): a small cluster consisting of 5
cell adhesion molecules (contactin 1 and 2, L1CAM, and neurocan
or CSPG3); and the largest cluster, consisting of 36 proteins,
including a large number of signaling and vesicle trafficking
proteins, such as N-type calcium channels (CACNA1B) and
cysteine string protein (CSP).
In the smaller cluster, morphine administration led to a decrease
in the levels of L1CAM in the PRE fraction, but not in the total
homogenate(Fig.4A). Adecreaseintheprocessedform ofneurocan
Table 1. Seed list of 30 proteins from the striatal PRE fraction that were altered by morphine treatment.
Gene Name Protein Name UniProt Acc. #
Downregulated (23)
Vesicle Trafficking
NSF N-ethylmaleimide sensitive factor Q9QUL6
AP2A2 AP-2 complex subunit alpha-2 P18484
STXBP1 Syntaxin-binding protein 1 (Unc-18 homolog) P61765
Signaling
GNAL GTP-binding protein Golf alpha subunit Q80WZ0
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1 P54311
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 2 P54313
GNB3 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 3 P52287
YWHAZ 14-3-3 protein zeta/delta P63102
Cytoskeleton-associated
SEPT3 G-septin gamma Q9R245
SEPT7 Septin 7 Q9WVC0
TUBB2B Tubulin beta chain 15 Q3KRE8
Cell Adhesion
CNTN1 Contactin 1 Q63198
NCAM1 Neural cell adhesion molecule 1, 140 kDa isoform P13596
OPCML Opioid-binding protein/cell adhesion molecule precursor (OBCAM) P32736
Chaperone
HSPA5 78 kDa glucose-regulated protein precursor (GRP 78) P06761
HSPA8 Heat shock cognate 71 kDa protein P63018
TCP1 T-complex protein 1 subunit alpha P28480
Mitochondrial-related
CS Citrate synthase, mitochondrial precursor Q8VHF5
DLD Dihydrolipoyl dehydrogenase Q6P6R2
HK1 Chain A, Rat Brain Hexokinase Type I Complex With Glucose And Inhibitor Glucose-6-Phosphate P05708
HK2 Hexokinase 2 P27881
VDAC2 Voltage-dependent anion-selective channel protein 2 P81155
VDAC3 Voltage-dependent anion-selective channel protein 3 Q9R1Z0
Upregulated (7)
Mitochondrial-related
ATP5C1 ATP synthase gamma chain, mitochondrial P35435
ATP5B ATP synthase subunit beta, mitochondrial precursor P10719
COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor P10888
COX5A Cytochrome c oxidase subunit Va P11240
COX5B Cytochrome c oxidase subunit Vb P12075
Kinase
CDC42BPA Serine/threonine-protein kinase MRCK alpha O54874
Other
HBB Beta-globin Q6PDU6
Proteins with morphine/saline ratios of at least 0.5 standard deviations from the mean and that showed consistent changes in at least 2 of the experiments were
selected. The numbers in parentheses indicate the number of proteins that were downregulated or upregulated.
doi:10.1371/journal.pone.0025535.t001
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homogenate fraction after morphine administration (Fig. 4B).
In the largest cluster, we identified CSP as a significant
intermediate (with the highest score of 6.45). Western blot analysis
showed a significant decrease in the levels of this protein in the PRE
fraction, but not in the total homogenate, after chronic morphine
administration (Fig. 4A). To determine whether chronic morphine
would also alter the levels of proteins that interact with CSP, we
used Western blotting to measure Hsp90 levels. In contrast to CSP,
chronic morphine led to an increase in Hsp90 levels in striatal PRE
fractions but not in the total homogenate (Fig. 5).
Naloxone-precipitated morphine withdrawal
To assess the behavioral implications of the observed increase in
Hsp90 levels, we examined the effect of Hsp90 inhibition on
naloxone-precipitated morphine withdrawal (Fig. 6). In morphine-
treated animals, administration of the selective Hsp90 inhibitor,
geldanamycin, led to a dose-dependent decrease in somatic signs of
withdrawal (Fig. 6B, Table 2). No significant effects were observed
in animals chronically exposed to saline in the absence or presence
of geldanamycin (Fig. 6A). After behavioral testing we used an
ELISA assay to determine the levels of Hsp90 in brainhomogenates
and PRE fractions under different treatment conditions. As
expected we observed an increase in Hsp90 levels in the PRE
fraction but not in the total brain homogenate of animals treated
chronically with morphine (Fig. 6C & D). This increase in Hsp90
levels in the PRE fraction was also observed following naloxone
administration, although a decrease was seen in brain homogenates
(Fig. 6C & D). Interestingly, the Hsp90 inhibitor, geldanamycin,
significantly increased the levels of Hsp90 in brain homogenates but
not in the PRE fraction of animals treated chronically with
morphine (Fig. 6C & D). Taken together these results suggest that
Hsp90 may play a role in dependence-associated behaviors.
Discussion
In this study, we undertook a quantitative subcellular proteomic
analysis to study the effects of morphine on striatal presynaptic
protein levels. We used a five-day paradigm of chronic
intermittent escalating morphine administration that results in
the development of significant opiate dependence [24], which is
considered to be due to neuroadaptations in the mesolimbic
system of the brain. This led to the identification of many proteins
that may play a role in the synaptic plasticity events underlying the
long-lasting and persistent effects of morphine in the brain.
Vesicle trafficking
Our analysis showed morphine-induced downregulation of most
of the proteins identified. Some of these are involved in various
steps of synaptic vesicle trafficking, including vesicle priming
(NSF), docking (syntaxin-binding protein 1 or Unc-18 homolog),
and endocytosis (AP-2 alpha2), supporting previous reports of
downregulation of SNARE complex formation [19,20] and NSF
upon morphine treatment [10]. Moreover, these results provide
additional information on the proteins involved in the synaptic
plasticity events thought to underlie addiction [25].
Cytoskeleton-associated and cell adhesion
Our proteomics data showed morphine-induced decreases in
several cytoskeleton-associated and cell adhesion molecules,
including tubulin beta chain 15, septin 3 and 7, contactin 1,
NCAM1, and opioid-binding cell adhesion molecule (OPCML or
OBCAM) (Table 1). Western blot analysis of contactin 1 and
NCAM 1 confirmed these results and showed that the decrease
was specific to the PRE fraction and not to total homogenate,
suggesting a redistribution of these proteins away from the
presynaptic nerve terminal, rather than a global decrease in their
expression levels. This is consistent with previous reports showing
that continuous morphine treatment decreases NCAM1 levels in a
synaptic membrane fraction
10. Taken together, these results
suggest a morphine-induced regulation of synapse architecture,
which could play an important role in long-term synaptic
plasticity. It is likely that other proteins at the presynapse are
similarly translocated upon morphine treatment, although the
mechanisms underlying this phenomenon remain unknown.
Similar results were observed for proteins predicted by our
network analysis to be modulated by morphine. For instance, a
decrease in processed neurocan was mostly seen in the PRE
fraction. This, taken with the finding that decreases in L1CAM
Figure 2. Validation of results from quantitative proteomics using Western blot analysis. The levels of NCAM and contactin 1 were
decreased in the striatal PRE fraction of morphine-treated animals, but not in the total homogenate. The decrease in presynaptic NCAM was observed
for the 180-, 140-, and 120-kDa isoforms of the protein.
doi:10.1371/journal.pone.0025535.g002
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further supports the novel concept of regulation of protein levels
by redistribution of proteins from PRE to extra-synaptic areas (as
opposed to changes in gene expression).
Signaling
Previously, it was shown that long-term exposure to morphine
leads to a decrease in the levels of several G protein subunits (ai2,
ai3, b1, b2) in human neuroblastoma SH-SY5Y cells stably
expressing the m opioid receptor [26]. Our results show that
chronic morphine treatment results in the downregulation of b1,
b2, b3, and aolf subunits of heterotrimeric G proteins, further
supporting the modulation of signaling proteins by morphine.
Interestingly, others have shown that this morphine-induced
downregulation of Gb seems to correlate with sensitization of
adenylyl cyclase, a hallmark of opiate dependence [26].
Chaperone
Another group of proteins, shown by our proteomics analysis to
be downregulated by chronic morphine administration, includes
molecular chaperones such as GRP 78, (Hsc70), and TCP1.
Hsc70, a constitutively expressed protein, is a member of the
70 kDA heat shock protein family (Hsp70). It is enriched in the
mammalian nervous system, particularly at synapses, where it
plays a role in the folding of denatured proteins [27,28]. It may
also have a neuroprotective role that preserves synaptic function
[28]. This protein also interacts with CSP, a member of the DnaJ
(or Hsp40) protein family found on synaptic vesicles and clathrin
coated vesicles in neurons [29]. Both proteins assemble into an
enzymatically active chaperone complex that associates with Gb,
increasing its inhibition of N-type calcium channels [30–32], and
this may be necessary for presynaptic neurotransmitter release
[33]. This complex may also facilitate protein interactions at
different stages of the vesicle trafficking cycle, regulating processes
at all stages of exocytosis, including neurotransmitter synthesis and
vesicle filling, docking, calcium entry, and vesicle fusion [34]. Our
results showed a decrease in both Hsc70 (data not shown) and CSP
in the PRE fraction upon morphine treatment, suggesting that
these two proteins may have a critical effect on presynaptic
function.
Figure 3. Network representation of proteins altered by morphine treatment. Proteins from the seed list (yellow) were connected via
intermediates from the background dataset. Significant intermediates are shown in red (score.3) or orange (score between 2–3). The two clusters
that were used to make predictions of morphine-regulated proteins are outlined.
doi:10.1371/journal.pone.0025535.g003
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levels of CSP and Hsc70, we sought to determine whether chronic
morphine administration would also affect the levels of Hsp90,
which is known to interact with these proteins under normal
conditions [34]. Our results showed an increase in presynaptic
Hsp90 levels after chronic morphine administration, suggesting a
morphine-induced dissociation of Hsp90 from the interacting
complex (i.e. from CSP and Hsc70) and recruitment to the
presynaptic terminal that may result in its association with other
yet-unidentified proteins at the presynapse. Additionally these
studies suggest that although some proteins may not be detected by
quantitative subcellular proteomic analysis, their presence can be
deduced through the identification of interacting proteins by a
combination of network and cluster analysis.
Naloxone-precipitated morphine withdrawal
To further assess the functional implications of the observed
increase in Hsp90 levels, we used a morphine withdrawal
paradigm to determine whether this increase plays a role in
morphine dependence. Our results showed that inhibition of
Hsp90 by geldanamycin dose-dependently decreases somatic signs
of morphine withdrawal, suggesting that Hsp90 may play an
important role in dependence-associated behaviors and that its
inhibition may alleviate symptoms of withdrawal in opiate-
dependent subjects. Moreover, Hsp90 inhibitors may represent
potential therapeutics to prevent the cellular adaptations to
chronic morphine administration, since it was recently shown
that inhibition of Hsp90 partially inhibits the adenylyl cyclase
superactivation observed after chronic morphine administration
[35]. Taken together, these studies suggest a provocative role for
molecular chaperones in mediating presynaptic events that may
underlie some of the long-lasting effects of morphine. In fact, there
is evidence to suggest that Hsp90 may play an important role in
neurotransmission [33,36], suggesting that the changes observed
after chronic morphine administration may be related to the role
of Hsp90 in neurotransmission and not necessarily a general
response to stress.
Morphine and other addictive drugs produce significant and
persistent adaptations at the synaptic level that may underlie their
long-lasting addictive potential [25]. We previously showed the
powerful potential that an integratedproteomicsand computational
approach has to make biologically relevant predictions that can be
tested experimentally [22]. Here we used this approach to gain a
better understanding of the presynaptic proteins, signaling path-
ways, and complexes that are regulated by morphine and to identify
potential targets for treatment of opiate dependence and addiction
(Figure S2). One of the major substrates of the molecular and
cellular mechanisms of opiate addiction is the striatum, which has
been implicated in reward, habit learning, craving and relapse. This
information on chronic morphine-induced changes in striatal
Figure 4. Validation of network analysis predictions. Using graph theory-based methods, L1CAM, neurocan (CSPG3), and CSP were predicted
to be decreased at the presynapse by morphine treatment. Western blot analysis showed a decrease in (A) L1CAM, CSP, and (B) a lower molecular
weight form of neurocan in the PRE fraction after chronic morphine administration. Protein levels were normalized to actin. A representative figure
(out of 6 blots) is shown; the graph with statistical data is from multiple determinations **p,0.01 compared to saline treated (n=6).
doi:10.1371/journal.pone.0025535.g004
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future studies on the roles of these proteins in addiction.
Furthermore, this study demonstrates that such an approach using
proteomic techniques in combination with computational graph
theory analysis, allows a unique and more complete understanding
of neurobiological networks at the presynapse and their regulation.
Materials and Methods
Animals and Drug Treatment
Protocols involving animals were conducted in accordance with
the recommendations set forth in the Guide for the Care and Use of
Laboratory Animals by the National Institutes of Health, and were
approved by the Institutional Animal Care and Use Committee at
Mount Sinai School of Medicine (Protocol Number 02-0805).
Adult male Sprague-Dawley rats (200–250 g) or C57BL/6 mice
(25–30 g) were maintained on a 12-h light/dark cycle and
provided with food and water ad libitum. Animals were allowed
to acclimatize to their environment for a week prior to drug
administration. Morphine sulfate (Sigma, St. Louis, MO, USA)
was prepared in 0.9% sterile isotonic saline. Animals were injected
intraperitoneally (i.p.) with saline or morphine for 5 days. In the
latter case, morphine was injected in escalating doses (5, 10, 15,
20, 25, 30, 35, 40 and 50 mg/kg) every 12 h. This intermittent,
escalating dose paradigm of morphine administration results in the
development of morphine dependence and withdrawal, and is
refered to as chronic morphine aministration in the field. Animals
were sacrificed 2 h after the last injection.
Subcellular Fractionation
After chronic morphine treatment, animals were sacrificed by
decapitation and the brains rapidly removed. Isolation of a
presynaptic (PRE) fraction was performed as previously de-
scribed [22]. The striata from 3 saline- or morphine-treated rats
were combined and homogenized in 3 ml of 0.32 M sucrose,
Figure 5. Hsp90 levels after chronic morphine administration.
Western blot analysis showed an increase in the levels of Hsp90 in the
PRE fraction after chronic morphine administration. No changes were
observed in total homogenates suggesting redistribution of the protein
rather than increases in gene expression changes. Protein levels were
normalized to actin. **p,0.01 compared to saline treated (n=6). A
representative blot of 6 is shown.
doi:10.1371/journal.pone.0025535.g005
Figure 6. The effect of geldanamycin on naloxone-precipitated
morphine withdrawal. (A & B) Mice treated chronically with saline
(A) or morphine (B) were injected with either geldanamycin (GA; 5 or
20 mg/kg i.p.) or vehicle (20% DMSO in 0.9% saline) 2 h after the last
injection, followed by naloxone (1 mg/kg s.c.) and withdrawal was
evaluated for a period of 30 min as described in Methods. Geldanamy-
cin (20 mg/kg) attenuates signs of morphine withdrawal. (C & D)
Following behavioral analysis animals were sacrificed and Hsp90 levels
were detected by ELISA in brain homogenates (C) and PRE fractions (D)
as described in Methods. Data represents Mean 6 SEM n=4–12/group.
doi:10.1371/journal.pone.0025535.g006
Table 2. The effect of geldanamycin on naloxone-
precipitated morphine withdrawal.
Withdrawal
Signs
Vehicle
(n=12)
GA (5 mg/kg)
(n=4)
GA (20 mg/kg)
(n=7)
Rearing 55.3367.87 32.86613.45 22.3369.38*
Jumping 37.1866.49 19.5614.66 2.8661.72**
Forepaw Tremors 54.4269.43 58.00619.84 21.2367.56
Teeth chattering 5.1760.45 2.7560.63* 1.5760.48***
Ptosis 4.4260.31 2.2560.75* 3.1460.51
Diarrhea 2.5860.52 0.2560.25* 0.4260.30**
*p,0.05,
**p,0.01,
***p,0.001 Vehicle vs GA.
doi:10.1371/journal.pone.0025535.t002
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inhibitor cocktails (Sigma, St. Louis, MO) at 4uC. All of the
following fractionation steps were carried out at 4uCu n l e s s
otherwise specified. The homogenate was brought to a final
concentration of 1.25 M sucrose by the addition of 2 M sucrose
(12 ml) and 0.1 mM CaCl2 (5 ml). The homogenate was then
placed in a 40 ml ultracentrifuge tube and overlaid with 10 ml
1 M sucrose, 0.1 mM CaCl2. The gradients were centrifuged at
100,000 g for 3 h. The synaptosomal fraction (4–5 ml) was
collected at the 1.25 M/1 M interface. To obtain synaptic
membranes, the synaptosomal fraction was brought to a volume
of 35 ml with 20 mM Tris-Cl pH 6, 0.1 mM CaCl2, containing
1% Triton X-100 (TX-100) and 350 ml each of protease and
phosphatase inhibitor cocktails, mixed for 20 min, and centri-
fuged at 40,000 g for 20 min. The pellet containing the isolated
synaptic membranes was collected. To separate a presynaptic
fraction from the post-synaptic density (PSD), the pellet was
resuspended in 20 ml of 20 mM Tris-Cl pH 8, 1% TX-100,
0.1 mM CaCl2. The mixture was again mixed for 20 min, and
centrifuged at 40,000 g for 20 min. The supernatant was
removed and concentrated to 1 ml using an Amicon Ultra-15
filter (5,000 MW cut-off, Millipore, Bedford, MA). The concen-
trate was precipitated with 9 ml of acetone by incubation at
220uC for 12 h, and centrifugation at 15,000 g for 30 min. The
resulting pellet, containing the PRE fraction, was stored at
280uC until use. We have previously shown that the PRE
fraction, isolated in this manner, is enriched in presynaptic
proteins and excludes proteins that are enriched in the PSD
fraction [22].
Tryptic Digestion and Isotopic Labeling
Labeling experiments were performed as described elsewhere
[19,20], using three independent pools of PRE fractions isolated
from three rats each. The pellet containing the PRE fraction was
resuspended and solubilized in 0.1% SDS to a final concentration
of 1 mg/mL. 30 mg of protein extract were reduced using a 1,4-
dithiothreitol (DTT) solution (200 mM DTT in 100 mM
NH4HCO3, pH 8–10) at 40uC for 1 h. The reduced proteins
were alkylated using 1 M iodoacetamide (IAM) in 100 mM
NH4HCO3 for 40 min at room temperature (RT) in the dark.
Unreacted IAM was quenched with the DTT solution for 1 h.
The alkylated proteins were precipitated with cold acetone
overnight, and the precipitate was pelleted by centrifugation
(15000 rpm, 40 min, 4uC), then dissolved in digestion buffer
(50 mM NH4HCO3, 1 M urea, pH 8–10), with 0.1 mg of trypsin
(Sigma) at 40uC for 3 h. The pH of the tryptic digests was then
adjusted to 9–10 with 1 M NaOH. For quantification, covalent
modification of the tryptic peptides was performed by adding
2 mL of light (2 M succinic anhydride in DMSO) or heavy (2 M
succinic [
2H4] anhydride in DMSO) label [37]. The samples were
vortexed and centrifuged, then incubated for 15 min at RT. The
pH of the solutions was readjusted to 9–10. The labeling
procedure was repeated 4 times with subsequent adjustment of
pH. Remaining unreacted isotopic labels were quenched using
10 mL of 2.5 M glycine for 1 h at RT. The light and heavy
isotope-labeled samples were then combined and desalted using a
PepClean
TM C18 spin column (Pierce), as per the manufacturer’s
protocol, and peptides eluted using 70% aqueous acetonitrile
solution. The solvent in the eluate was removed using a vacuum
centrifuge, and the residue containing the peptides was
reconstituted in 20 mL of solvent A (5% aqueous acetonitrile
with 0.1% FA and 0.01% TFA in water). 10 mL aliquots from
each sample were used for LC-MS/MS analysis as described
below.
Mass Spectrometry
Peptide separation and MS analysis were performed using a
capLC
TM (Micromass, UK) system coupled to an HCTUltra-
PTM Discovery system ion-trap mass spectrometer (Bruker
Daltonics, Billerica, MA, USA) equipped with an electrospray
ionization source. The sample was injected using a manual
injector (Valco Instruments Co, Inc., TX, USA) and loaded onto a
trap column (PepMap
TM, C18, 5 mm, 100 A ˚, LC Packings) using
solvent A and washed for 5 min. The trapped peptides were then
eluted in the reverse direction onto a reverse phased capillary
column (LC Packings
TM 300 mm i.d.615 cm, C18 PepMap100,
100 A ˚) using a solvent gradient at a flow rate of 2 mL/min. The
solvent gradient was generated using solvent A and solvent B (95%
aqueous acetonitrile with 0.1% FA and 0.01% TFA in water). The
70 min gradient run for LC separation included 3 steps: 5–80%
solvent B in 15–55 min (linear); 80% solvent B for 55–60 min
(isocratic); 80–5% solvent B in 60–65 min (linear). MS data
acquisition and the subsequent MS/MS of selected peaks were
performed in a data-dependent manner using the Esquire software
(Bruker Daltonics). For each MS scan, three peptides were selected
to be fragmented, for 300–500 ms, based on their charge
(preferably +2) and intensity. Dynamic exclusion of previously
fragmented precursor ions was set to 2 spectra for a period of 60 s.
The MS and MS/MS scan were performed in the range of m/z
300–1500 and 50–2000 respectively.
Protein Identification and Quantification
The data were processed using the Data analysis software
(Bruker Daltonics). MS data obtained between 20 and 45 min of
the LC run was searched for compounds using an automated
search option. The short-listed compounds with their respective
MS/MS scans were directly exported to Biotools software (Bruker)
for database searching using an in-house Mascot database search
engine (Matrix Science). The mass tolerance of this study was set
at 0.1% for MS and 0.5 Da for MS/MS. The search parameters
included fixed modifications for cysteine (carbamidomethyl) and
variable modifications for methionine (Met-oxidized), succinic
anhydride or succinic [
2H4] anhydride modified lysine and N-
terminal amines. With Mascot, every tandem mass spectrum was
assigned a list of matching database peptide sequences accompa-
nied by a score representing the quality of each sequence
identification. A Mascot score of 50 is commonly used as a cut-
off for 95% confident identification. Only proteins identified with
a Mascot score $60 for every peptide were considered for further
analysis (for further experimental details on these measurements
see references [37,38]). For quantification, peak pairs with mass
differences of 2, 4 or 8 Da, a retention time window of 30 s, and a
signal-to-noise intensity .10 were listed using Data Analysis
software, along with their peak intensity ratios and retention times.
The morphine/saline ratio for each protein reflects the average of
ratios obtained for each of the isotopically labeled tryptic peptides
identified. During data acquisition only one of the labeled peptides
was selected for fragmentation. In several cases, peptide peak pairs
were manually identified and quantified.
Integration of Proteomics Data into a PPI Network
The proteins altered by morphine treatment were placed in the
context of signaling pathways and protein complexes using the
software tool Genes2Networks (http://actin.pharm.mssm.edu/
genes2networks) [21]. Genes2Networks integrates the contents of
10 mammalian binary interaction network datasets: BIND [39],
DIP [40,41], HPRD [42], IntAct [43], Ma’ayan [44], MINT [45],
Stelzl [46], Vidal [47], PDZBase [48], and PPID [49]. To this, we
added our own presynaptic PPI network dataset, http://amp.
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ground dataset before filtering contained 11,053 nodes and
44,985 links, with nodes representing the proteins, and links
representing direct protein-protein interactions. To decrease the
level of false positives resulting from high-throughput experiments,
the dataset was filtered to exclude interactions originating from
articles that provided five or more interactions. The final, filtered
background dataset contained 2,788 nodes and 19,695 links. The
proteins we identified as altered in the presynapse were connected
using a maximum of two intermediates from the background
dataset (path length of two nodes and three links). The resultant
network was visualized using the signaling network analysis and
visualization integrator (SNAVI) software package [50].
Network Analysis – Significant Intermediates and
Clustering
A binomial proportions test was used to evaluate the
significance of interactions between proteins from the background
dataset with the seed list. The z-sore (referred to as ‘‘score’’) for
each protein from the background dataset was computed as
described previously [21,22]. A higher score for a protein would
indicate that the number of its interactions with proteins from our
experimentally determined seed list is significantly enriched
compared with the number of its interactions with other proteins
from the background network. In this analysis, we considered
proteins with a score between 2–3 to be significant interactors with
proteins from the seed list, and proteins with a score between .3
to be highly significant. Cfinder (http://www.cfinder.org/) [51]
was used to locate and visualize clusters in the PPI network
containing the proteins altered by morphine treatment and the
intermediates connecting them. CFinder uses the clique percola-
tion method to locate k-clique percolation clusters in the network
[52]. A k-clique is defined as a complete, or fully connected,
subgraph on k nodes within the cluster. Two k-cliques are
considered adjacent if they share k-1 nodes, i.e. if they differ only
in a single node. A k-clique percolation cluster consists of a
maximal k-clique-connected subgraph, i.e. the union of all k-
cliques that can be reached via chains of adjacent k-cliques, and
the links in these cliques. This method allows the identification of
overlapping clusters, such that a single node can belong to more
than one cluster.
Western Blotting
10 mg of protein from each fraction were resolved in 7.5% SDS-
PAGE and analyzed by Western blots with the following
antibodies: CSP (1:3000, Stressgen, Victoria, BC), a-contactin
(1:1000, gift from J Salzer, NYU), neurocan (1:2000, gift from R.
Margolis, NYU) L1CAM (1:5,000, gift from D. Felsenfeld,
MSSM), NCAM1 (gift from G. Phillips, MSSM), Hsp90
(1:10,000, Stressgen), Hsp70 (1:10,000, Stressgen), actin
(1:10,000, Sigma).
Naloxone-Precipitated Morphine Withdrawal
C57BL/6 adult male mice (20–25 g) were injected with chronic
morphine or saline (i.p.) as described above (n=4–12 animals per
group). Two hours after the last injection, animals were injected
with geldanamycin (5 or 20 mg/kg i.p.) or vehicle (20% DMSO in
0.9% saline), followed by naloxone (1 mg/kg s.c.). After naloxone
injection, six somatic signs of withdrawal were evaluated for a
period of 30 min. Three signs (jumping, rearing and forepaw
tremors) were counted and three signs (teeth chattering, ptosis and
diarrhea) received a score of 1 for every 5-min interval in which it
was present. After behavioral tests were complete, animals were
sacrificed, brains were extracted and used to prepare homogenate
and PRE fractions as described above. Hsp90 levels in these
fractions were determined by ELISA as described previously [53]
using 10 mg protein, 1:2000 dilution of Hsp90 antibody and
1:2000 dilution of HRP conjugated anti-rabbit antibody.
Supporting Information
Figure S1 Clusters identified in the network of proteins altered
by morphine treatment. Clusters were identified and visualized
using CFinder, which uses the clique percolation method to
identify overlapping clusters. A total of 13 overlapping clusters
were identified in the network: 3 clusters with k=4 and 10 clusters
with k=3.
(TIF)
Figure S2 A flow chart summarizing the process of proteomic
data analysis and computational predictions. Simplified schematic
of the approaches used to identify morphine-regulated presynaptic
proteins by quantitative proteomics, and to map potential
presynaptic signaling pathways and protein complexes by graph
theory. These were then used to predict novel morphine-regulated
proteins. F=forward labeling, R=reverse labeling. The number
of proteins quantified is indicated in parentheses.
(TIF)
Table S1 Each sample represents a pool of 3 striatal PRE
fractions from saline- and morphine-treated rats. In total, 175
unique proteins were identified, and 143 of these were quantified.
Proteins identified were those with Mascot scores $60.
(DOC)
Table S2 Analysis of MS/MS spectra led to the identification of
175 proteins, 143 of which were quantified by determining the
peak intensity of the labeled peptides. Only 30 of these proteins
were robustly and consistently altered by morphine treatment.
(DOC)
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